Healthcare Global Enterprises Limited — PPTs, 19-05-2026: Investor Presentation

HealthCare Global Enterprises (HCG) posted solid Q4 and FY26 results.

**Business Performance:** Q4 revenue grew 11% YoY to ₹652.3 Cr, while FY26 revenue rose 15% YoY to ₹2,545.4 Cr. Adjusted EBITDA for FY26 increased 19% YoY to ₹471.1 Cr, with margins expanding to 18.5%. Growth was broad-based, with West, South, and East clusters seeing strong double-digit revenue growth. International business also surged 71% YoY in FY26.

**Growth Drivers/Strategy:** HCG is sharpening its focus on core oncology, exiting the non-core fertility business (Milann) to redeploy capital towards oncology expansion. The strategy emphasizes profitable growth through prudent capital allocation and enhancing network efficiency.

**Recent Developments:** The North Bangalore facility commenced operations, introducing MR-LINAC technology. A rights issue was completed, strengthening the balance sheet and funding growth. The company also launched Theranostics and expanded robotic surgery. Key leadership hirings were finalized.

**Key Financial Metrics:** FY26 Return on Capital Employed (ROCE) stood at 14.0%. Net Debt (including leases) significantly reduced from ₹1,466.7 Cr to ₹1,163.6 Cr, improving Net Debt/EBITDA to 1.43x from 2.27x.

**Management Commentary/Outlook:** Management plans further brownfield expansion of over 200 beds in the next two years across key cities, aiming to leverage existing network potential and drive margin improvement as centers mature.